The Phase 1 study is a first-in-human, multicenter, open-label trial designed to evaluate the safety, tolerability, ...

Mumbai: Vasai resident Dhruv (name changed) has been battling a brain tumour since 2018 and underwent surgery in 2022. But ...

Sionna Therapeutics (NASDAQ:SION) used its presentation at the Guggenheim Emerging Outlook Biotech Summit 2026 to outline its strategy to develop next-generation cystic fibrosis (CF) therapies ...

ImmuneSensor Therapeutics, a clinical-stage biotherapeutics company focused on the development of first- and best-in-class cGAS inhibitors to address diverse peripheral and CNS indications in ...

ImmuneSensor Therapeutics, a clinical-stage biotherapeutics company focused on the development of first- and best-in-class cGAS inhibitors to address diverse peripheral and CNS indications ...

Oral presentation to highlight updated Phase 1 monotherapy safety and efficacy data for TOS-358, a covalent PI3Ka inhibitorData will include ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Q4 2025 Earnings Call Transcript February 12, 2026 Vertex Pharmaceuticals ...

Discusses Positive Phase 3 PROPEL 3 Results for Infigratinib in Children With Achondroplasia February 12, 2026 8:00 ...

Q4 2025 Earnings Call February 10, 2026 6:45 AM ESTCompany ParticipantsAndrew Barnett - Head of Investor RelationsPascal Soriot - ...

The PROTAC market is experiencing rapid growth, driven by rising interest in targeted protein degradation as a next-generation therapeutic approach. Expanding oncology pipelines with drugs in clinical ...

Detailed price information for Royalty Pharma Plc Cl A (RPRX-Q) from The Globe and Mail including charting and trades.